Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Pfizer Inc. (NYSE:PFE)

Posted by Stuart Ham on Apr 9th, 2025

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $15,001 and $50,000 in Pfizer stock on March 31st. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Purchased $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 4/1/2025.
Sold $1,001 – $15,000 in shares of W. R. Berkley (NYSE:WRB) on 4/1/2025.
Sold $15,001 – $50,000 in shares of GoDaddy (NYSE:GDDY) on 4/1/2025.
Purchased $1,001 – $15,000 in shares of Ford Motor (NYSE:F) on 3/31/2025.
Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 3/31/2025.
Purchased $1,001 – $15,000 in shares of Boeing (NYSE:BA) on 3/31/2025.
Sold $1,001 – $15,000 in shares of Hologic (NASDAQ:HOLX) on 3/31/2025.
Sold $15,001 – $50,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 3/31/2025.
Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/31/2025.
Sold $1,001 – $15,000 in shares of Viatris (NASDAQ:VTRS) on 3/31/2025.

Pfizer Price Performance

PFE stock opened at $21.75 on Wednesday. Pfizer Inc. has a 1 year low of $20.78 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $123.33 billion, a price-to-earnings ratio of 15.42, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a 50 day simple moving average of $25.59 and a 200 day simple moving average of $26.58.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the company earned $0.10 EPS. Pfizer’s revenue was up 24.7% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on PFE. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday. Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group cut their price target on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a report on Tuesday. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $31.07.

Check Out Our Latest Report on PFE

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On Pfizer

Institutional investors and hedge funds have recently modified their holdings of the business. Nordea Investment Management AB boosted its stake in Pfizer by 36.1% during the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after acquiring an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI boosted its position in shares of Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock worth $7,820,000 after purchasing an additional 159,984 shares in the last quarter. Copley Financial Group Inc. acquired a new stake in shares of Pfizer in the 3rd quarter valued at about $577,000. Geode Capital Management LLC increased its position in Pfizer by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company’s stock valued at $3,392,342,000 after buying an additional 1,855,419 shares in the last quarter. Finally, Mcdonald Partners LLC raised its stake in Pfizer by 9.9% during the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock worth $2,926,000 after buying an additional 9,963 shares during the period. 68.36% of the stock is currently owned by institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.